Studies show that increased H3K9me3 in the Slc2a4 promoter enhancer segment reduces GLUT4 expression in skeletal muscle and worsens glycemic control in diabetes, pointing to H3K9me3 of the Slc2a4 promoter as a potential target for treating diabetes [63]. The gene discussed is SLC2A4; the disease is diabetes mellitus.